AU2023249068A1 - Combination therapies comprising gdc-6036 and gdc-0077 for the treatment of cancer - Google Patents

Combination therapies comprising gdc-6036 and gdc-0077 for the treatment of cancer Download PDF

Info

Publication number
AU2023249068A1
AU2023249068A1 AU2023249068A AU2023249068A AU2023249068A1 AU 2023249068 A1 AU2023249068 A1 AU 2023249068A1 AU 2023249068 A AU2023249068 A AU 2023249068A AU 2023249068 A AU2023249068 A AU 2023249068A AU 2023249068 A1 AU2023249068 A1 AU 2023249068A1
Authority
AU
Australia
Prior art keywords
gdc
administered
pharmaceutically acceptable
acceptable salt
inavolisib
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023249068A
Other languages
English (en)
Inventor
Neekesh Vijay DHARIA
Stephanie Royer JOO
Mark Andrew MERCHANT
Jennifer Lee SCHUTZMAN
Zhen Shi
Chunyan Song
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AU2023249068A1 publication Critical patent/AU2023249068A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2023249068A 2022-04-06 2023-04-04 Combination therapies comprising gdc-6036 and gdc-0077 for the treatment of cancer Pending AU2023249068A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263328149P 2022-04-06 2022-04-06
US63/328,149 2022-04-06
PCT/US2023/017455 WO2023196329A1 (en) 2022-04-06 2023-04-04 Combination therapies comprising gdc-6036 and gdc-0077 for the treatment of cancer

Publications (1)

Publication Number Publication Date
AU2023249068A1 true AU2023249068A1 (en) 2024-09-05

Family

ID=86286527

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023249068A Pending AU2023249068A1 (en) 2022-04-06 2023-04-04 Combination therapies comprising gdc-6036 and gdc-0077 for the treatment of cancer

Country Status (13)

Country Link
US (2) US12383557B2 (cg-RX-API-DMAC7.html)
EP (1) EP4504202B1 (cg-RX-API-DMAC7.html)
JP (1) JP2025511352A (cg-RX-API-DMAC7.html)
KR (1) KR20240167654A (cg-RX-API-DMAC7.html)
CN (1) CN119013026A (cg-RX-API-DMAC7.html)
AU (1) AU2023249068A1 (cg-RX-API-DMAC7.html)
CA (1) CA3255718A1 (cg-RX-API-DMAC7.html)
ES (1) ES3067080T3 (cg-RX-API-DMAC7.html)
IL (1) IL315250A (cg-RX-API-DMAC7.html)
MX (1) MX2024012230A (cg-RX-API-DMAC7.html)
PL (1) PL4504202T3 (cg-RX-API-DMAC7.html)
TW (1) TW202345846A (cg-RX-API-DMAC7.html)
WO (1) WO2023196329A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250000802A1 (en) * 2023-06-09 2025-01-02 Hoffmann-La Roche Inc. Solid formulations comprising an inhibitor of the k-ras protein having a g12c mutation, and a process for preparing

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111909173B (zh) 2015-07-02 2025-03-04 豪夫迈·罗氏有限公司 苯并氧氮杂䓬噁唑烷酮化合物及其使用方法
KR20210035211A (ko) * 2018-07-23 2021-03-31 에프. 호프만-라 로슈 아게 Pi3k 저해제인 gdc-0077로 암을 치료하는 방법
WO2020097537A2 (en) 2018-11-09 2020-05-14 Genentech, Inc. Fused ring compounds
TWI829003B (zh) 2020-08-12 2024-01-11 美商建南德克公司 喹唑啉化合物之合成
EP4243827A1 (en) 2020-11-13 2023-09-20 Genentech, Inc. Methods and compositions comprising a krasg12c inhibitor and a pd-l1 binding antagonist for treating lung cancer
KR102975432B1 (ko) 2020-11-13 2026-06-10 제넨테크, 인크. 고형 종양 치료를 위한 krasg12c 억제제 및 vegf 억제제를 포함하는 방법 및 조성물
TWI895563B (zh) 2020-12-08 2025-09-01 美商建南德克公司 用於治療實性瘤之包含krasg12c抑制劑及egfr抑制劑之組成物及方法
AR128449A1 (es) 2022-02-07 2024-05-08 Genentech Inc Proceso para la síntesis de compuestos de quinazolina
CN118742544A (zh) 2022-02-07 2024-10-01 基因泰克公司 1-((s)-4-((r)-7-(6-氨基-4-甲基-3-(三氟甲基)吡啶-2-基)-6-氯-8-氟-2-(((s)-1-甲基吡咯烷-2-基)甲氧基)喹唑啉-4-基)-3-甲基哌嗪-1-基)丙-2-烯-1-酮的固体形式

Also Published As

Publication number Publication date
US12383557B2 (en) 2025-08-12
EP4504202A1 (en) 2025-02-12
US20230321102A1 (en) 2023-10-12
IL315250A (en) 2024-10-01
CN119013026A (zh) 2024-11-22
KR20240167654A (ko) 2024-11-27
PL4504202T3 (pl) 2026-05-04
ES3067080T3 (en) 2026-05-19
TW202345846A (zh) 2023-12-01
CA3255718A1 (en) 2023-10-12
JP2025511352A (ja) 2025-04-15
US20260053802A1 (en) 2026-02-26
MX2024012230A (es) 2024-11-08
EP4504202B1 (en) 2026-02-04
WO2023196329A1 (en) 2023-10-12

Similar Documents

Publication Publication Date Title
WO2017013160A1 (en) 4-amino-6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8h)-one for treatment of solid cancers
JP6716585B2 (ja) 結腸直腸癌の処置に使用するためのアピリモド
JP2017503842A (ja) 癌治療のためのアピリモド(apilimod)組成物
US12409178B2 (en) Methods and compositions comprising a KRasG12C inhibitor and a VEGF inhibitor for treating solid tumors
KR20250069693A (ko) 암 치료
US20260053802A1 (en) TREATMENT OF CANCER USING COMBINATION THERAPIES COMPRISING GDC-6036 and GDC-0077
TW202329946A (zh) 用於治療癌症之方法及包含cdk2抑制劑之給藥方案
AU2021397214B2 (en) Methods and compositions comprising a krasg12c inhibitor and a egfr-inhibitor for treating solid tumors
CN121969373A (zh) 使用mta协作的prmt5抑制剂的癌症治疗
HK40118757A (en) Combination therapies comprising gdc-6036 and gdc-0077 for the treatment of cancer
CA2869152A1 (en) Methods for treating cancer using pi3k inhibitor and mek inhibitor
HK40126893A (en) Dosage regimen for sotorasib/carboplatin/pemetrexed in cancer treatment
HK40094176A (en) Methods and compositions comprising a krasg12c inhibitor and a vegf inhibitor for treating solid tumors
JP2024531653A (ja) 固形腫瘍の処置のための経口投与パクリタキセル、P-gp阻害剤、およびチェックポイント阻害剤の治療的組み合わせ
TW201315471A (zh) 使用PI3Kβ抑制劑及包括MEK及RAF抑制劑之MAPK通道抑制劑之供治療癌症之組合物及方法